Related Experiment Video

Updated: Nov 26, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K

I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer

Haiyun Wang1, Douglas Yee1

  • 1Masonic Cancer Center, University of Minnesota, MMC 806, 420 Delaware St SE, Minneapolis, MN 55455, USA.

Current Breast Cancer Reports
|December 14, 2020
PubMed
Abstract

Insights

The I-SPY 2 trial uses an adaptive design to test new breast cancer drugs, aiming for better outcomes in high-risk patients. This innovative approach personalizes treatment by classifying tumors into subtypes for targeted therapies.

Area of Science:

  • Oncology
  • Clinical Trials
  • Translational Research

Background:

  • High-risk breast cancer requires innovative treatment strategies.
  • The neoadjuvant setting offers opportunities for early drug evaluation.
  • Traditional clinical trials may not adequately address tumor heterogeneity.

Purpose of the Study:

  • To review the background, structure, innovation, and outcomes of the I-SPY 2 trial.
  • To highlight the adaptive clinical trial platform's design.
  • To discuss the trial's contribution to precision medicine in breast cancer.

Main Methods:

  • Bayesian adaptive randomization for individualized patient assignment.
  • Classification of breast cancer into 10 subtypes using clinical biomarkers.
  • Evaluation of novel agents in combination with standard therapy.

Main Results:

  • Pathologic complete response (pCR) as the primary endpoint.
  • Seven novel agents have successfully graduated from the I-SPY 2 trial.
  • Ongoing enrollment of multiple new agents in active treatment arms.

Conclusions:

  • The I-SPY 2 trial demonstrates the success of an individualized approach in clinical trial design.
  • This platform aims to improve outcomes for high-risk breast cancer patients.
  • Further research and innovation are encouraged to advance precise treatment options.
Keywords:
Adaptive randomizationBreast cancerI-SPY 2Neoadjuvant chemotherapyPathological complete response

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.5K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.9K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.3K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
533
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K